Novo Nordisk A/S (NYSE:NVO) Shares Up 10.1% – What’s Next?

Novo Nordisk A/S (NYSE:NVO) shares shot up 10.1% during mid-day trading on Friday . The company traded as high as $47.74 and last traded at $47.71. 35,810,167 shares were traded during trading, an increase of 34% from the average session volume of 26,703,395 shares. The stock had previously closed at $43.34.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA says it will target mass-marketed, unapproved compounded drug copies, which reduces the competitive threat from low-cost copycats and helped lift sentiment. Novo Nordisk shares rebound as FDA targets illegal drug copies – Reuters
• Positive Sentiment: Some analysts view the recent selloff as overdone and argue NVO’s strong cash flow, first-mover Wegovy advantages and promising pipeline (CagriSema) make the pullback a buying opportunity for long-term holders. Novo Nordisk: The Selloff Is A Blessing In Disguise – Seeking Alpha
• Positive Sentiment: Novo has announced it will pursue legal action against Hims & Hers over compounded Wegovy copies — a defensive step that could limit spread of low-cost alternatives if successful. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding – Reuters
• Neutral Sentiment: Company disclosure shows trading by board members and executives — useful for monitoring insider behavior but not immediately directional. Trading in Novo Nordisk shares by board members, executives – GlobeNewswire
• Neutral Sentiment: Company declared a dividend (record/ex-dividend dates published) — supportive for income investors but not a cure for near-term volume/price headwinds.
• Negative Sentiment: Hims & Hers launched a $49–$99 compounded oral semaglutide offering, sharply undercutting Wegovy’s price and triggering market panic about pricing erosion and access to cheap compounding alternatives. Hims and Hers Health launches copy of Wegovy pill at $49 – Reuters
• Negative Sentiment: Citi warns that inability to curb compounded semaglutide use is a lingering risk to Novo’s pricing power and investor sentiment. Citi flags lingering risks to Novo despite strong weight-loss portfolio – Proactive Investors
• Negative Sentiment: Competitive dynamics: Eli Lilly’s strong guidance and manufacturing scale are shifting market share and investor preference toward Lilly, increasing near-term pressure on Novo’s revenue outlook. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles – MarketBeat
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell for the first time, highlighting geographic and competitive pressures. Novo reports first Ozempic sales drop in greater China region – Reuters

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Citigroup started coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. CICC Research started coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective on the stock. Morgan Stanley reiterated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Finally, TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Price Performance

The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company’s fifty day moving average price is $53.64 and its 200 day moving average price is $54.06. The firm has a market capitalization of $213.03 billion, a price-to-earnings ratio of 13.75 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 72.86% and a net margin of 33.03%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Revolve Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC raised its holdings in Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its stake in Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after buying an additional 1,587 shares in the last quarter. Simplicity Wealth LLC boosted its holdings in shares of Novo Nordisk A/S by 7.5% in the second quarter. Simplicity Wealth LLC now owns 3,423 shares of the company’s stock worth $236,000 after buying an additional 240 shares during the period. Finally, Belpointe Asset Management LLC increased its position in shares of Novo Nordisk A/S by 28.6% in the second quarter. Belpointe Asset Management LLC now owns 13,617 shares of the company’s stock worth $940,000 after acquiring an additional 3,028 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.